Reviewer’s report
Title: 
CCDC114, DNAI2 and TOP2A  involves in the effects of Tibolone
treatment on postmenopausal endometrium
Version: 
0 
Date: 
10 Jan 2020
Reviewer: 
Ibrahim A.
Reviewer's report:
Dear Respectable Editor 
Thank you to give me the opportunity to review the manuscript entitled
(Potential molecular mechanism investigation of Tibolone treatment for
postmenopausal women). 
The study aimed to explore the molecular mechanism of Tibolone in
postmenopausal women. Gene expression profile GSE12446 including 9 human
endometrial samples from postmenopausal women treated with Tibolone
(Tibolone group) and 9 control samples (control group) prepared and the
differentially expressed genes (DEGs) investigated, followed by function and
pathway enrichment on these DEGs. Then the protein-protein interaction
network (PPI) and modules analysis w performed. The drug-target interaction
and novel drugs prediction performed based on DEGs obtained in this study.
Authors concluded that the up-regulated Coiled-Coil Domain Containing 114
and Dynein Axonemal Intermediate Chain 2 might play important roles in
Tibolone-treated postmenopausal women via cilium movement function.
Moreover, Tibolone might affect the regulation of SLE pathway in
postmenopausal women. DNA Topoisomerase II A might be a breakthrough for
novel drugs investigation for postmenopausal women. Furthermore, Epirubicin
might be a clinical alternative medicine to Tibolone.
Authors provided structured abstract. 
In the introduction, authors provided the magnitude of the problem and provided
good reason why their study was designed and conducted (In postmenopausal
women, coronary artery disease, osteoporosis as well as endometrial disease are
major causes of mortality and morbidity. Tibolone show effect on inhibiting the
development of postmenopausal women associated disease via influencing the
serum total homocysteine levels and bone loss in postmenopausal women.
Previous studies showed a close relationship between Tibolone treatment and
gene expression in the women endometrium). So, their study designed to explore
the detail molecular mechanism of Tibolone in postmenopausal women.
Method section, authors mentioned the microarray data, data processing and
DEGs analysis, function and pathway analysis, PPI network construction and
modules analysis, gene-target interaction analysis and gene-target drugs
prediction.
Results section, authors provided their results in a clear simplified way with
clear figures.
Discussion section, authors compared their findings with others, and they used a
relevant references. In addition, they mentioned the limitation faced and the
future recommended researches. 
Finally, manuscript presents an important and interesting subject and can be
accepted for publication after correction of minor spelling and typing errors
(page 5; yellow highlighted).
Regards 
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
Yes
Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the
authors.
Yes
Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes
Are you able to assess any statistics in the manuscript or would you
recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects
require further assessment in your comments to the editors.
I recommend additional statistical review
Quality of written English
Please indicate the quality of language in the manuscript:
Acceptable
Declaration of competing interests
Please complete a declaration of competing interests, considering the following
questions:
1
. 
Have you in the past five years received reimbursements, fees, funding, or
salary from an organisation that may in any way gain or lose financially
from the publication of this manuscript, either now or in the future?
2
. 
Do you hold any stocks or shares in an organisation that may in any way
gain or lose financially from the publication of this manuscript, either now
or in the future?
3
. 
Do you hold or are you currently applying for any patents relating to the
content of the manuscript?
4
. 
Have you received reimbursements, fees, funding, or salary from an
organization that holds or has applied for patents relating to the content of
the manuscript?
5
. 
Do you have any other financial competing interests?
6
. 
Do you have any non-financial competing interests in relation to this
paper?
If you can answer no to all of the above, write 'I declare that I have no competing
interests' below. If your reply is yes to any, please give details below.
I declare that I have no competing interest
I agree to the open peer review policy of the journal. I understand that my name
will be included on my report to the authors and, if the manuscript is accepted
for publication, my named report including any attachments I upload will be
posted on the website along with the authors' responses. I agree for my report to
be made available under an Open Access Creative Commons CC-BY license
(
http://creativecommons.org/licenses/by/4.0/
). I understand that any comments
which I do not wish to be included in my named report can be included as
confidential comments to the editors, which will not be published.
I agree to the open peer review policy of the journal